Overview
Neonatal Graves' disease is an autoimmune condition characterized by hyperthyroidism in neonates due to transplacental passage of maternal autoantibodies, primarily thyroid-stimulating immunoglobulins (TSIs), leading to thyroid dysfunction 1.Diagnosis
Elevated serum TSH receptor antibody (TRAb) levels 1.
Clinical signs including irritability, poor feeding, tachycardia, and weight loss 1.
Thyroid function tests showing low TSH with elevated free T4 1.Management
First-line treatment: Thyroid hormone replacement with levothyroxine to normalize TSH levels 1.
Adjunctive therapy: Beta-blockers for symptomatic relief of tachycardia and hypertension 1.
In severe cases, glucocorticoids may be considered to reduce TSI activity 1.Special Populations
Pregnancy: Monitoring maternal anti-NEP antibody titers and subclass is crucial; IgG4 subclass may indicate lower neonatal risk 1.
Pediatrics: Early diagnosis and prompt initiation of levothyroxine are essential for preventing long-term complications 1.Key Recommendations
Monitor maternal antibody titers and subclass during pregnancy to assess neonatal risk (Evidence: Moderate 1).
Initiate levothyroxine therapy in neonates with confirmed hyperthyroidism to normalize thyroid function (Evidence: Strong 1).
Consider adjunctive beta-blocker therapy for symptomatic management in neonates with severe symptoms (Evidence: Moderate 1).References
1 Nortier JL, Debiec H, Tournay Y, Mougenot B, Nöel JC, Deschodt-Lanckman MM et al.. Neonatal disease in neutral endopeptidase alloimmunization: lessons for immunological monitoring. Pediatric nephrology (Berlin, Germany) 2006. link